Poland· PL-100475252
Nolicin
A norfloxacin product containing norfloxacinum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Norfloxacin is registered in 11 of 19 countries.
Countries holding a registration under ATC J01MA06 (norfloxacin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Norfloxacin · ATC J01MA06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Germany
- Italyprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of norfloxacin costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $0.65 in Italy to $3.00 in Switzerland — a ×4.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Norfloxacin · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.00
- IT Italy$0.65
The record
At a glance
URPL (Poland)- Active substance
- Norfloxacinum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- J01MA06
- ATC class
- Norfloxacin
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991499815
- gtin05909991499822
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
467 interactions on record for norfloxacin.
Graded by severity as the source publishes them — 86 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Norfloxacin · interactions on record
467 records
- 86 severe
- 219 moderate
- 51 minor
- 42 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PrednisoloneA07EA01severe
69 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Norfloxacin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGYRABLOCKMedochemie Ltd., Limassol
- SpainNORFLOXACINO CINFA 400 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFGLaboratorios Cinfa S.A.
- FinlandFloxanorratiopharm Oy
- FranceNORFLOXACINE ARROW 400 mg, comprimé pelliculéARROW GENERIQUES
- NetherlandsNorfloxacine CF 400 mg, omhulde tablettenCentrafarm B.V.
- ItalyNORFLOXACINA SANDOZSANDOZ S.P.A.
- BelgiumNorfloxacine EG 400 mgEG
- United KingdomNorfloxacin 400mg tabletsKent Pharma (UK) Ltd
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Floxacin Stada, Norfloxacin Sandoz
- Bulgaria · Нолицин
- Cyprus · Gyrablock, Trizolin
- Czechia · Gyrablock, Nolicin
- Germany · Norfloxa, Norfloxacin 1 A Pharma
- Estonia · Nolicin
- Spain · Chibroxin, Norfloxacino Cinfa
- France · Chibroxine, Norfloxacine Biogaran
- Greece · Fluseminal, Norocin
- Croatia · Noflox, Nolicin
- Hungary · Nolicin, Nolicin-S
- Italy · Naflox, Norfloxacina Abc
- Lithuania · Nolicin
- Latvia · Nolicin, Norflox
- Malta · Norfloxacin Helcor
- Netherlands · Norfloxacine Cf, Norfloxacine Sandoz
- Portugal · Chibroxol, Norfloxacina Vitória
- Romania · Nolicin, Norfloxacin Helcor
- Slovenia · Nolicin
- Slovakia · Gyrablock, Nolicin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b981122d-f883-4c69-8355-64a09fb3b849 GET /v1/drugs/b981122d-f883-4c69-8355-64a09fb3b849?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "400 mg",
"packaging": "05909991499815 ¦ Rp ¦ 147429\n10 tabl.\n05909991499822 ¦ Rp ¦ 147430\n20 tabl.",
"substance": "Norfloxacinum 400 mg",
"common_name": "Norfloxacinum",
"pl_product_id": "100475252",
"pozwolenie_nr": "392/22",
"auth_procedure": "IR",
"authorisation_validity": "2027-10-26"
}See everything about norfloxacin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.